76 related articles for article (PubMed ID: 37648261)
1. Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.
Shah BD; Cassaday RD; Park JH; Houot R; Oluwole OO; Logan AC; Boissel N; Leguay T; Bishop MR; Topp MS; Tzachanis D; O'Dwyer KM; Arellano ML; Lin Y; Baer MR; Schiller GJ; Subklewe M; Abedi M; Minnema MC; Wierda WG; DeAngelo DJ; Stiff PJ; Jeyakumar D; Mao D; Adhikary S; Zhou L; Schuberth PC; Damico Khalid R; Ghobadia A
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37648261
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of patients aged ≥26 years with relapsed or refractory B-cell acute lymphoblastic leukemia in ZUMA-3 and historical trials.
Minnema MC; Yin X; Davi R; Keeping S; Park JE; Itani T; Hadjivassileva T; Castaigne JG; Damico Khalid R; Zhou L; Wu JJ; Shah BD
Leuk Lymphoma; 2024 May; ():1-10. PubMed ID: 38785408
[TBL] [Abstract][Full Text] [Related]
3. Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium.
Wang Y; Jain P; Locke FL; Maurer MJ; Frank MJ; Munoz JL; Dahiya S; Beitinjaneh AM; Jacobs MT; Mcguirk JP; Vose JM; Goy A; Andreadis C; Hill BT; Dorritie KA; Oluwole OO; Deol A; Paludo J; Shah B; Wang T; Banerjee R; Miklos DB; Rapoport AP; Lekakis L; Ghobadi A; Neelapu SS; Lin Y; Wang ML; Jain MD
J Clin Oncol; 2023 May; 41(14):2594-2606. PubMed ID: 36753699
[TBL] [Abstract][Full Text] [Related]
4. Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor.
Salles G; Chen JMH; Zhang I; Kerbauy F; Wu JJ; Wade SW; Nunes A; Feng C; Kloos I; Peng W; Snider JT; Maciel D; Chan K; Keeping S; Shah B
Adv Ther; 2024 May; 41(5):1938-1952. PubMed ID: 38494543
[TBL] [Abstract][Full Text] [Related]
5. Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study.
Htut M; Dhakal B; Cohen AD; Martin T; Berdeja JG; Usmani SZ; Agha M; Jackson CC; Madduri D; Deraedt W; Zudaire E; Yeh TM; Xu X; Pacaud L; Akram M; Jagannath S
Clin Lymphoma Myeloma Leuk; 2023 Dec; 23(12):882-888. PubMed ID: 37716872
[TBL] [Abstract][Full Text] [Related]
6. [Safety and efficacy of donor-derived chimeric antigen receptor T-cell therapy in patients with relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
Zhuo YQ; Tu SF; Zhou X; Yang JL; Zhou LJ; Huang R; Huang YX; Li MF; Jin B; Wang B; Li SQ; Yuan ZT; Zhang LH; Liu L; Wang SB; Li YH
Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):74-81. PubMed ID: 38527842
[No Abstract] [Full Text] [Related]
7. [Treatment response of a two-dose regimen of dose-adjusted inotuzumab ozogamicin in relapsed/refractory B-cell acute lymphoblastic leukemia].
An LL; Zhao DF; Hou RF; Guan HH; Yan H; Lin YH; Tong CR; Wu T; Liu SY
Zhonghua Xue Ye Xue Za Zhi; 2023 Nov; 44(11):911-916. PubMed ID: 38185520
[No Abstract] [Full Text] [Related]
8. Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma.
Hess G; Dreyling M; Oberic L; Gine E; Zinzani PL; Linton K; Vilmar A; Jerkeman M; Chen JMH; Ohler A; Stilgenbauer S; Thieblemont C; Lambert J; Zilioli VR; Sancho JM; Jimenez-Ubieto A; Fischer L; Eyre TA; Keeping S; Park JE; Wu JJ; Nunes A; Reitan J; Wade SW; Salles G
Leuk Lymphoma; 2024 Jan; 65(1):14-25. PubMed ID: 37840282
[TBL] [Abstract][Full Text] [Related]
9. Real-world experience of commercial relmacabtagene autoleucel (relma-cel) for relapsed/refractory central nervous system lymphoma: a multicenter retrospective analysis of patients in China.
Yu W; Huang L; Mei H; Li Y; Niu T; Zou D; Liu Y; Zhang H; Liu P; Wu J; Wang Z; Li H; Cai Q; Mi JQ
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38802271
[TBL] [Abstract][Full Text] [Related]
10. Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell Lymphoma.
Chong EA; Chong ER; Therwhanger D; Nasta SD; Landsburg DJ; Barta SK; Svoboda J; Gerson JN; Ghilardi G; Paruzzo L; Fraietta JA; Weber E; Stefano N; Porter DL; Frey NV; Garfall AL; Ruella M; Schuster SJ
Transplant Cell Ther; 2024 Mar; ():. PubMed ID: 38494076
[TBL] [Abstract][Full Text] [Related]
11. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real-world intention-to-treat analysis.
O'Reilly MA; Wilson W; Burns D; Kuhnl A; Seymour F; Uttenthal B; Besley C; Alajangi R; Creasey T; Paneesha S; Elliot J; Gonzalez Arias C; Iyengar S; Wilson MR; Delaney A; Rubio L; Lambert J; Begg K; Boyle S; Cheok KPL; Collins GP; Roddie C; Johnson R; Sanderson R
Hemasphere; 2024 Jun; 8(6):e87. PubMed ID: 38873532
[TBL] [Abstract][Full Text] [Related]
12. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).
Neelapu SS; Chavez JC; Sehgal AR; Epperla N; Ulrickson M; Bachy E; Munshi PN; Casulo C; Maloney DG; de Vos S; Reshef R; Leslie LA; Oluwole OO; Yakoub-Agha I; Khanal R; Rosenblatt J; Korn R; Peng W; Lui C; Wulff J; Shen R; Poddar S; Jung AS; Miao H; Beygi S; Jacobson CA
Blood; 2024 Feb; 143(6):496-506. PubMed ID: 37879047
[TBL] [Abstract][Full Text] [Related]
13. CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies.
Zhang LN; Song Y; Liu D
J Hematol Oncol; 2018 Mar; 11(1):41. PubMed ID: 29544528
[TBL] [Abstract][Full Text] [Related]
14. A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia.
Short NJ; Jabbour E; Jain N; Senapati J; Nasr L; Haddad FG; Li Z; Hsiao YC; Yang JJ; Pemmaraju N; Ohanian M; Wierda WG; Montalban-Bravo G; Borthakur G; Han L; Xiao L; Huang X; Abramova R; Zhao M; Garris R; Konopleva M; Ravandi F; Kantarjian H
Blood Adv; 2024 Feb; 8(4):909-915. PubMed ID: 38207208
[TBL] [Abstract][Full Text] [Related]
15. Practice Preferences for Consolidative Hematopoietic Stem Cell Transplantation Following Tisagenlecleucel in Children and Young Adults with B Cell Acute Lymphoblastic Leukemia.
McNerney KO; Moskop A; Winestone LE; Baggott C; Talano JA; Schiff D; Rossoff J; Modi A; Verneris MR; Laetsch TW; Schultz L
Transplant Cell Ther; 2024 Jan; 30(1):75.e1-75.e11. PubMed ID: 37816472
[TBL] [Abstract][Full Text] [Related]
16. Consolidation with First and Second Allogeneic Transplants in Adults with Relapsed/Refractory B-ALL Following Response to CD19CAR T Cell Therapy.
Aldoss I; Shan H; Yang D; Clark MC; Malki MA; Aribi A; Agrawal V; Sandhu K; Salhotra A; Pourhassan H; Koller P; Ali H; Artz A; Karras N; Pawlowska AB; Murphy L; Palmer J; Stein A; Marcucci G; Pullarkat V; Nakamura R; Forman SJ
Transplant Cell Ther; 2024 Jun; ():. PubMed ID: 38876428
[TBL] [Abstract][Full Text] [Related]
17. Comparison of blinatumomab and CAR T-cell therapy in relapsed/refractory acute lymphoblastic leukemia: a systematic review and meta-analysis.
Zhai Y; Hong J; Wang J; Jiang Y; Wu W; Lv Y; Guo J; Tian L; Sun H; Li Y; Li C; Zhan H; Zhao Z
Expert Rev Hematol; 2024; 17(1-3):67-76. PubMed ID: 38135295
[TBL] [Abstract][Full Text] [Related]
18. Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme.
Oporto Espuelas M; Burridge S; Kirkwood AA; Bonney D; Watts K; Shenton G; Jalowiec KA; O'Reilly MA; Roddie C; Castleton A; Clesham K; Nicholson E; Alajangi R; Prabhu S; George L; Uttenthal B; Gabelli M; Neill L; Besley C; Chaganti S; Wynn RF; Bartram J; Chiesa R; Lucchini G; Pavasovic V; Rao A; Rao K; Silva J; Samarasinghe S; Vora A; Clark P; Cummins M; Marks DI; Amrolia P; Hough R; Ghorashian S
Blood Cancer J; 2024 Apr; 14(1):66. PubMed ID: 38622139
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma.
Marchetti M; Visco C
Leuk Lymphoma; 2023; 64(8):1442-1450. PubMed ID: 37229538
[TBL] [Abstract][Full Text] [Related]
20. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001.
Abramson JS; Palomba ML; Gordon LI; Lunning M; Wang M; Arnason J; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Dehner C; Kim Y; Ogasawara K; Kostic A; Siddiqi T
Blood; 2024 Feb; 143(5):404-416. PubMed ID: 37890149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
